-
Mashup Score: 1Mark Geyer, M.D. (@markgeyermd.bsky.social) - 6 hour(s) ago
Leukemia/cell therapy doc; Adolescent/Young Adult and ALL Leukemia Program Leader at Memorial Sloan Kettering Cancer Center. Indie rock and Boston sports fan. Opinions=my own. đź’–đź’śđź’™ https://www.mskcc.org/cancer-care/doctors/mark-geyer
Source: bsky.appCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Opinion | Venezuela Is Ready for Change. Maduro Must Allow It. - 5 month(s) ago
It is clear Venezuelans have chosen to oust President Maduro. Whether that will happen remains in question.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet-
The world is watching Venezuela. Maduro has threatened a “bloodbath” if he’s not re-elected--hoping for as safe, free, and fair of an election as possible. https://t.co/lYAZlMlM5D https://t.co/cx4Gp5WW6r
-
-
Mashup Score: 12A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 - 5 month(s) ago
Key Points. Using an intensive pediatric regimen for AYAs with ALL is feasible.High rates of EFS and OS were seen compared with historical controls.
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
How should we incorporate blina into pediatric regimens such as CALGB 10403 (https://t.co/X2jSXpauDy) and pediatric inspired regimens (including https://t.co/qflBSyjbJS)? Can we remove blocks of intensive chemo? And what about SC blina to spare the need for a central line? This… https://t.co/UZ9oJjRWFl
-
-
Mashup Score: 0
Strategies for Preventing and Managing Tumor Lysis Syndrome-Associated Conditions
Source: www.vumedi.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Happy to have collaborated with Drs. Scott Howard and Joshua Elder on this Vumedi video regarding tumor lysis syndrome prevention and management in the modern era (including w/ potent agents like venetoclax)! #leusm @lymsm https://t.co/KKDopprdee
-
-
Mashup Score: 0Boston Marathon legend Rick Hoyt dies at 61 - The Boston Globe - 2 year(s) ago
Rick Hoyt, who for years completed the Boston Marathon in a wheelchair famously pushed by his father, died Monday morning, a little more than two years after his dad’s death, the family said.
Source: BostonGlobe.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RIP to Boston Marathon icon Rick Hoyt, preceded in death by his father, Dick--two of my greatest inspirations as a runner. https://t.co/bilZmwGTXv
-
-
Mashup Score: 0Fact check: No evidence Texas Sen. Ted Cruz has a Twitter template for mass shootings - 2 year(s) ago
USA TODAY found no evidence that Sen. Ted Cruz, R-Texas, has a Twitter template he uses in response to mass shootings.
Source: USA TODAYCategories: Hem/Oncs, Latest HeadlinesTweet-
@rosslevinemd FYI this is not true: https://t.co/VXeHebLwWa
-
-
Mashup Score: 4Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients - 2 year(s) ago
AbstractAims. Chimeric antigen receptor T-cell therapy (CAR-T) harnesses a patient’s immune system to target cancer. There are sparse existing data characterizi
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet-
Congratulations to @SaadMahmoodMD and others on putting together this sizable registry study of severe cardiovascular events post CAR T-cell therapy, now in #EHJ @ESC_Journals. Higher inflammatory markers and more NRM in pts w/ severe cardiac toxicity. https://t.co/HlbEVAZXqG https://t.co/JNqYZUkraB
-
-
Mashup Score: 0Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant - Nature Communications - 2 year(s) ago
Multiple myeloma (MM) is treated with induction chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. Here, the authors show that the presence of clonal haematopoiesis of indeterminate potential (CHIP) at time of ASCT is associated with adverse outcomes in MM patients.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
@RenoHemonc @BloodAdvances Unclear--in this paper, CH was not associated w/ risk of t-MN in MM pts, but small #s and it does appear that CH clones present prior to autologous HCT may drive subsequent therapy-related myeloid neoplasia in some (https://t.co/f7btRidcFG).
-
-
Mashup Score: 0Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms - PubMed - 2 year(s) ago
There is a growing body of evidence that therapy-related myeloid neoplasms (t-MNs) with driver gene mutations arise in the background of clonal hematopoiesis (CH) under the positive selective pressure of chemo- and radiation therapies. Uncovering the exposure relationships that provide selective adv …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
We know lenalidomide leads to degradation of IKZF1/3, essential transcription factors in myeloma and tumor suppressors in ALL. Lenalidomide also appears to promote the outgrowth of TP53-mutated HSPCs (see terrific work by Sperling et al. https://t.co/IaYL6r5oWk). (3/x) https://t.co/t83cIDNShc
-
-
Mashup Score: 2Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal - 2 year(s) ago
Key Points. Lenalidomide associated B-ALL has high rates of TP53 mutation and hypodiploidy.Combination chemotherapy, antigen-targeted therapies, and allogeneic
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Happy to share our MSK/Ohio State collaborative effort on lenalidomide-associated ALL, now available in @BloodAdvances: https://t.co/CFO86N4RSB. (1/x).
-
Wishing everyone on here a happy and healthy holiday season! Closing this account on Dec 24th. #MedSky and #MedTwitter friends/colleagues: feel free to follow me on at https://t.co/rEKlRjo6F6.